Efgartigimod alfa (Vyvgart) for Myasthenia Gravis
Date: April 18, 2022
Issue #:
1648Summary:
Efgartigimod alfa-fcab (Vyvgart– Argenx), a first-in-class neonatal Fc receptor (FcRn) antagonist,
has been approved by the FDA for IV treatment of
generalized myasthenia gravis in adults who are
anti-acetylcholine receptor (AChR) antibody positive.
The IV complement inhibitor eculizumab(Soliris) was
approved for the same indication in 2017.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: azathioprine cyclosporine corticosteroids eculizumab efgartigimod alfa methotrexate rituximab myasthenia gravis Pyridostigmine Tacrolimus Vyvgart Source Type: research
More News: Corticosteroid Therapy | Drugs & Pharmacology | Methotrexate | Myasthenia Gravis | Perinatology & Neonatology | Prograf | Restasis | Rituxan | Tacrolimus